Literature DB >> 25606085

Should Statins Be Started In All Type 2 Diabetics Irrespective of LDL-Cholesterol Level?

Ss Vasanthakumar1, Cl Teng2.   

Abstract

Entities:  

Year:  2007        PMID： 25606085      PMCID： PMC4170335     

Source DB:  PubMed          Journal:  Malays Fam Physician        ISSN： 1985-2274


× No keyword cloud information.
  7 in total

1.  Standards of medical care in diabetes--2007.

Authors: 
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

Review 2.  Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials.

Authors:  Paaladinesh Thavendiranathan; Akshay Bagai; M Alan Brookhart; Niteesh K Choudhry
Journal:  Arch Intern Med       Date:  2006-11-27

3.  Diabetes and coronary risk equivalency: what does it mean?

Authors:  Scott M Grundy
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

4.  Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).

Authors:  Robert H Knopp; Michael d'Emden; Johan G Smilde; Stuart J Pocock
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

5.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

Review 6.  Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians.

Authors:  Sandeep Vijan; Rodney A Hayward
Journal:  Ann Intern Med       Date:  2004-04-20       Impact factor: 25.391

7.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleigh; Richard Peto
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.